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Remission of Cap Polyposis Maintained for More Than Three 
Years after Infliximab Treatment
Eun Sun Kim, Yoon Tae Jeen, Bora Keum, Yeon Seok Seo, Hoon Jai Chun, Soon Ho Um, 
Chang Duck Kim, and Ho Sang Ryu
Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea
Cap polyposis is a rare disorder with characteristic 
endoscopic and histological features; its etiology is 
still unknown, and no specific treatment has been 
established. We report a case of cap polyposis that 
improved remarkably after infliximab infusion and had 
no recurrence for 3 years. (Gut and Liver 2009;3: 
325-328)
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INTRODUCTION
  Cap polyposis is a rare but distinct disorder with char-
acteristic endoscopic and histological features.
1,2 It is 
characterized by multiple distinctive erythematous, in-
flammatory colonic polyps located from the rectum to the 
distal colon. And the polyps are covered with fibrinopur-
ulent mucus which appears like a ‘cap.’ The common 
symptoms are mucous and bloody diarrhea with abdomi-
nal pain and tenesmus. The etiology of this disease is still 
unknown, and no specific treatment has been established. 
There have been a few reports about the cases of cap pol-
yposis responsive to infliximab.
3 Herein we report a cap 
polyposis that was remarkably improved after a single in-
fliximab infusion and had no recurrence for 3 years.
CASE REPORT
  A 58-year-old woman was admitted to our hospital be-
cause of mucous bloody stools, frequent defecation and 
tenesmus for 2 weeks. One month ago, the patient had 
been managed in other hospital with 2nd generation 
cephalosporin antibiotics because of community acquired 
pneumonia. On physical examination, abdomen was soft 
and there was no tenderness or palpable mass. Hemoglo-
bin was 14.5 g/dL, white blood cell count was 6,380/mm
3, 
platelet count was 319,000/mm
3 and data of C-reactive 
protein or erythrocyte sedimentation rate were not in-
creased. Stool occult blood test was positive, but, 
Clostridium difficile antigen assay of stool was negative. 
  Colonoscopy showed about 20 reddish sessile polyps 
covered with white purulent exudates, and scattered hy-
peremia on rectum and sigmoid colon. The polyps were 
located on apices of mucosal fold (Fig. 1). The histo-
logical finding of sessile polyp indicated chronic and acute 
inflammations with acute cryptitis. We first diagnosed 
pseudomembranous colitis based on patient’s history of 
antibiotics administration and colonoscopic finding. How-
ever, there was no clinical symptom improvement after 
oral administration of 250 mg metronidazol qid for 3 
weeks.
  The colonoscopic finding for follow up showed no im-
provement, and additional biopsy was performed. Histo-
logical finding showed that the polyps were consisted of 
elongated, tortuous, and hyperplastic crypts that attenu-
ated toward the surface (Fig. 2). Heavy infiltration of in-
flammatory cells, ulcerated mucosal surface and fi-
brinopurulent exudates are characteristic of the so-called 
“cap polyp.” On the basis of these characteristic colono-
scopic and histologic findings, therefore, the patient was 
diagnosed with cap polyposis. 
  We considered conservative management and bowel ha-326   Gut and Liver, Vol. 3, No. 4, December 2009
Fig. 3. Colonoscopy conducted 4 weeks after infliximab 
i n f u s i o n  r e v e a l e d  r e d u c t i o n s  i n  t h e  s i z e  a n d  n u m b e r  o f  t h e  
sessile polyps.
Fig. 4. Follow-up colonoscopy conducted 36 months after the 
single infusion of infliximab, revealing maintenance of the 
4-week postinfusion state (i.e., no recurrence of cap polyposis).
Fig. 1. S e s s i l e  p o l y p s  w i t h  e x u d a t e s  a n d  h y p e r e m i a  i n  t h e  
sigmoid colon.
Fig. 2. Histological findings. The polyps comprise elongated, 
tortuous, and hyperplastic crypts that attenuate toward the 
surface. Heavy infiltration of inflammatory cells, an ulcerated 
mucosal surface, and fibrinopurulent exudates are characteristic
of the so-called “cap polyp” (H&E stain, ×100).
bitual correction to avoid straining at defecation. After 12 
months of these managements, there was no improve-
ment of clinical symptom and colonoscopic finding. Then, 
we considered surgical management or infliximab infusion. 
Therefore, we first administered 5 mg/kg dose of infli-
ximab. At 7th days, following the infliximab infusion, 
clinical improvement occurred. After 4 weeks of in-
fliximab infusion, colonoscopy revealed that the multiple 
sessile polyps decreased in size and numbers (Fig. 3), and 
no side effect of infliximab was observed. Therefore, we 
decided to follow up the patient with no additional ad-
ministration of infliximab. For 3 years, the patient experi-
enced no clinical symptom recurrence, and the last colo-
noscopy revealed almost complete mucosal recovery ex-
cept for tiny scant scars (Fig. 4).
DISCUSSION
Common clinical manifestation of cap polyposis is mu-
cous bloody diarrhea lasting for weeks to months, and 
women are mostly afflicted. Tenesmus, rectal bleeding, 
abdominal pain, constipation, weight loss, and hypo-
proteinemia have also been reported.
3,4 Epidemiology and 
etiology of cap polyposis have not been well known. Kim ES, et al: Cap Polypsis Treatment with Infliximab Infusion and Long Term Follow Up   327
Table 1. Case Reports of Cap Polyposis and Treatments
Case  Gender  Age  Symptom  Location  Management  Follow up duration Result 
Campbell  et al.  Male 68 Weight loss, Sigmoid colon Total colectomy     − Improved
 (1993)
2
 diarrhea
  Female 65 Diarreha Rectum Cleversal enema     − Improved
Gehenot  et al.  Female 42 Bloody  Rectosigmoid Sigmoid colostomy  9 months Resolved 
 (1994)
6 
diarrhea
Shiomi et al.  Female 54 Hypoproteinemia,  Descending  Left hemicolectomy      − Resolved 
 (1998)
7 
diarrhea   colon
Oriuchi et al.  Female 20 Hypoproteinemia,  Rectosigmoid Avoidance of   4 years Impreved
 (2000)
8 
mucous diarrhea  straining
Female 52 Hypoproteinemia,  Rectosigmoid Colostomy for      − Improved 
 mucous diarrhea  avoid constipation
Kajihara et al.  Female 38 Bloody diarrhea Rectosigmoid Metronidazole   2 months Resolved 
 (2000)
9
Isomoto  et al.  Female 51 Mucous, bloody  Rectosigmoid Sigmoid colostomy  1 year Resolved 
 (2001)
10  
diarrhea
Esaki  et al.  Male 21 Weight loss,  Rectosigmoid Metronidazole   6 months Transiently 
 (2001)
11  
bloody diarrhea  improved 
Female 67 Abdominal pain,  Rectosigmoid Proctosig-  18 months Resolved
 mucous diarrhea  moidectomy
Male 21 Abdominal  Rectum  Refuse      - Improved 
 discomfort  (only symptom)
Female 76 Mucous diarrhea,  Rectosigmoid Refuse  22 months Sustained 
 tenesmus  tenesmus 
Sadamoto  et al.  Male 73 No symptom From sigmoid  No treatment  4 months Resolved 
 (2001)
12  
to cecum 
Oiya  et al.  Male 63 Mucous diarrhea From rectum to  Helicobacter   8 months Resolved 
 (2002)
13  
ascending   eradication
 colon
Shimizu  et al.  Female 12 Mucous bloody  Rectosigmoid Metronidazole 12 months Resolved
 (2002)
5 
diarrhea
Park  et al.  Female 60 Abdominal pain,  Rectum Surgical resection  6 months Resolved
 (2002)
14  
tenesmus
Ohkawara  et al.  Female 67 Mucous bloody  Rectosigmoid No treatment 12 months Resolved
 (2003)
15  
diarrhea
Akamatsu  et al. Female 33 Hypoproteinemia,  Rectum  Helicobacter 18  months Resolved 
 (2004)
16  
mucous bloody  eradication
 stool
Female 50 Weight loss,  Rectosigmoid Helicobacter 26  months Resolved 
 mucous bloody   eradication
 stool
Female 53 Mucous bloody  Rectosigmoid Helicobacter  15 months Resovled 
 stool  eradication
Bookman  et al.  Female 36 Abdominal pain,  Rectosigmoid Infliximab infusion 38 months Resolved 
 (2004)
3 
mucous bloody
 diarrhea
Konishi  et al.  Female 76 Hypoproteinemia,  Total colon Sigmoid colostomy  3 months Resolved 
 (2005)
17  
mucous bloody
 stool
Maunoury  et al.  Female 52 Abdominal pain,  Rectum  Imfliximab      − Failed 
 (2005)
18  
mucous   infusion
 diarrhea
Ryu  et al.  Male 64 Weight loss,  Rectosigmoid Conservative   1 year Resolved 
 (2006)
19  
diarrhea
Several suggestions have been made on its pathogenesis, 
including a form of inflammatory bowel disease, an in-
fectious origin such as Helicobacter pylori or Escherica coli 
018, improvement after antibiotics treatment,
5,6  whereas 
other suggested on association with mucosal prolapse 
syndrome or abnormal colonic motility resulting in local 328   Gut and Liver, Vol. 3, No. 4, December 2009
ischemia and recurrent mucosal trauma.
5,6 Diagnosis of 
this disease in the present case was established through 
colonoscopic finding, clinical manifestation and histo-
logical finding. The endoscopic finding showed eryth-
ematous polyps with adherent fibrinopurulent exudates 
like a cap, and this finding resembled inflammatory polyp 
or pseudomembranous colitis. The microscopic finding re-
vealed elongated hyperplastic glands with inflammatory 
infiltrate in the lamina propria and fibromuscular ob-
literation of lamina propria. The cap of polyp is formed 
by mucus, fibrin, and inflammatory cells.
1,3 
  Several case reports have suggested a few treatment 
modalities, based on etiological hypothesis; anti-inflam-
matory agent, antibiotics, immunomodulators, and endo-
scopic and surgical therapy (Table 1). However optimal 
treatment has not yet been established. The effectiveness 
and administration schedule of infliximab for cap poly-
posis also have not yet been established. One report de-
scribed complete remission after four infusions of in-
fliximab at 0, 8, 12, and 24 weeks, however another re-
ports showed no benefit after a similar treatment.
3,9 In 
our present case, the patient fortunately achieved remark-
able clinical, endoscopic and histological responses after 
single infusion of infliximab. The short term response of 
our patient was published in Korean.
20 Our present case 
is the long term follow up result after 3 years. 
Furthermore, resolution of the disease maintained for 36 
months. Consequently, our present case might support 
the hypothesis that inflammation has some role in the 
pathogenesis of cap polyposis.
3 Of course, additional stud-
ies about cap polyposis treated with infliximab infusion, 
including its optimal dosage and administration schedule, 
are needed. Nevertheless we suggest that infliximab 
might be a good treatment modality for cap polyposis pa-
tients who are refractory to conservative management.
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